GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Gross Profit

IsoPlexis (IsoPlexis) Gross Profit : $-0.93 Mil (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Gross Profit?

IsoPlexis's gross profit for the three months ended in Dec. 2022 was $-7.81 Mil. IsoPlexis's gross profit for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.93 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. IsoPlexis's gross profit for the three months ended in Dec. 2022 was $-7.81 Mil. IsoPlexis's Revenue for the three months ended in Dec. 2022 was $3.36 Mil. Therefore, IsoPlexis's Gross Margin % for the quarter that ended in Dec. 2022 was -232.49%.

IsoPlexis had a gross margin of -232.49% for the quarter that ended in Dec. 2022 => No sustainable competitive advantage

During the past 4 years, the highest Gross Margin % of IsoPlexis was 56.59%. The lowest was -5.52%. And the median was 51.45%.


IsoPlexis Gross Profit Historical Data

The historical data trend for IsoPlexis's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis Gross Profit Chart

IsoPlexis Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Gross Profit
4.25 5.41 8.77 -0.93

IsoPlexis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.56 2.08 2.26 -7.81

Competitive Comparison of IsoPlexis's Gross Profit

For the Medical Devices subindustry, IsoPlexis's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IsoPlexis's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's Gross Profit distribution charts can be found below:

* The bar in red indicates where IsoPlexis's Gross Profit falls into.



IsoPlexis Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

IsoPlexis's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=16.761 - 17.686
=-0.93

IsoPlexis's Gross Profit for the quarter that ended in Dec. 2022 is calculated as

Gross Profit (Q: Dec. 2022 )=Revenue - Cost of Goods Sold
=3.361 - 11.175
=-7.81

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.93 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

IsoPlexis's Gross Margin % for the quarter that ended in Dec. 2022 is calculated as

Gross Margin % (Q: Dec. 2022 )=Gross Profit (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=-7.81 / 3.361
=-232.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


IsoPlexis  (NAS:ISO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

IsoPlexis had a gross margin of -232.49% for the quarter that ended in Dec. 2022 => No sustainable competitive advantage


IsoPlexis Gross Profit Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


IsoPlexis (IsoPlexis) Business Description

Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003